Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary Kaohsiung Medical University Chung-Ho Memorial Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
First MR-Linac in Taiwan Provides Patients Access to MR-Guided Radiation Therapy CLEVELAND , Aug. 5, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) in Kaohsiung City, Taiwan has begun patient treatments with the
Toggle Summary ViewRay Reports Second Quarter 2020 Results
CLEVELAND , July 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020 .     Second Quarter 2020 Highlights: Total revenue of $14.2 million , primarily from two revenue units, compared to $30.2 million , primarily from
Toggle Summary ViewRay Announces Conference Call for Second Quarter 2020 Financial Results to be Held After Market on July 30, 2020
CLEVELAND , July 13, 2020 /PRNewswire/ --   ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2020 financial results.     ViewRay will hold a conference call to discuss results on Thursday, July 30, 2020 at 4:30 p.m. ET / 1:30 p.m. PT .
Toggle Summary ViewRay Announces 1-Year Outcomes on MR-Guided Radiation Treatment for Prostate Cancer Without Implanted Markers
Study Shows Low Incidence of Toxicity Using Stereotactic Body Radiation Therapy (SBRT) While Reducing Potential Complications Associated with Implanted Markers CLEVELAND , June 23, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today the publication by the European Urology Oncology

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Financial Events
More events are coming soon.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select